Your browser is no longer supported. Please, upgrade your browser.
Cellectar Biosciences, Inc.
Index- P/E- EPS (ttm)-0.95 Insider Own0.40% Shs Outstand52.73M Perf Week-5.15%
Market Cap68.01M Forward P/E- EPS next Y-0.48 Insider Trans60.11% Shs Float40.70M Perf Month-7.86%
Income-15.10M PEG- EPS next Q-0.10 Inst Own43.90% Short Float4.62% Perf Quarter-48.40%
Sales- P/S- EPS this Y58.50% Inst Trans0.26% Short Ratio1.60 Perf Half Y11.21%
Book/sh1.17 P/B1.10 EPS next Y-9.10% ROA-54.00% Target Price- Perf Year-7.86%
Cash/sh1.08 P/C1.19 EPS next 5Y- ROE-83.00% 52W Range1.01 - 2.98 Perf YTD-37.98%
Dividend- P/FCF- EPS past 5Y59.50% ROI- 52W High-56.71% Beta1.64
Dividend %- Quick Ratio16.30 Sales past 5Y- Gross Margin- 52W Low27.72% ATR0.10
Employees11 Current Ratio16.30 Sales Q/Q- Oper. Margin- RSI (14)35.59 Volatility7.94% 7.43%
OptionableNo Debt/Eq0.00 EPS Q/Q66.10% Profit Margin- Rel Volume0.32 Prev Close1.25
ShortableYes LT Debt/Eq0.00 EarningsMar 02 BMO Payout- Avg Volume1.18M Price1.29
Recom1.60 SMA20-11.61% SMA50-19.25% SMA200-19.42% Volume372,664 Change3.20%
Jul-01-20Initiated Oppenheimer Outperform
Jan-21-20Resumed ROTH Capital Buy $10
Sep-13-19Initiated ROTH Capital Buy
Dec-21-16Initiated Ladenburg Thalmann Buy $2.70
May-14-21 09:00AM  
May-10-21 08:30AM  
Apr-27-21 08:39AM  
Mar-28-21 04:29AM  
Mar-11-21 08:30AM  
Mar-09-21 09:00AM  
Mar-05-21 08:30AM  
Mar-02-21 08:30AM  
Feb-10-21 08:30AM  
Jan-27-21 08:30AM  
Jan-12-21 09:09AM  
Dec-28-20 04:05PM  
Dec-23-20 08:39AM  
Dec-22-20 05:28PM  
Dec-06-20 02:12AM  
Dec-01-20 11:35AM  
Nov-27-20 04:13PM  
Nov-09-20 08:44AM  
Nov-05-20 09:00AM  
Sep-10-20 08:00AM  
Sep-09-20 08:00AM  
Aug-17-20 10:01AM  
Aug-10-20 08:00AM  
Aug-04-20 08:00AM  
Jul-29-20 03:31PM  
Jul-21-20 08:00AM  
Jul-01-20 08:00AM  
Jun-11-20 08:30AM  
Jun-09-20 06:33AM  
Jun-05-20 04:01PM  
Jun-03-20 09:00AM  
Jun-01-20 08:00AM  
May-28-20 10:10AM  
May-27-20 10:56AM  
May-26-20 07:45AM  
May-14-20 08:00AM  
May-07-20 08:15AM  
Apr-16-20 07:04AM  
Mar-09-20 08:00AM  
Feb-19-20 08:00AM  
Jan-17-20 06:41AM  
Jan-09-20 08:00AM  
Jan-07-20 08:00AM  
Jan-06-20 08:00AM  
Dec-19-19 08:00AM  
Dec-16-19 08:00AM  
Dec-13-19 08:31AM  
Dec-09-19 08:30AM  
Dec-02-19 08:30AM  
Nov-12-19 08:00AM  
Oct-30-19 08:00AM  
Oct-19-19 09:44AM  
Oct-17-19 08:00AM  
Oct-15-19 08:00AM  
Oct-08-19 08:00AM  
Sep-30-19 08:30AM  
Sep-24-19 08:00AM  
Sep-19-19 08:30AM  
Sep-16-19 08:30AM  
Sep-10-19 08:00AM  
Sep-04-19 08:00AM  
Aug-20-19 12:37PM  
Aug-15-19 08:30AM  
Aug-14-19 08:30AM  
Aug-12-19 08:00AM  
Jul-09-19 08:30AM  
May-21-19 08:30AM  
May-20-19 04:10PM  
May-18-19 07:15AM  
May-16-19 08:52AM  
May-15-19 08:30AM  
May-13-19 08:00AM  
May-06-19 08:00AM  
May-02-19 02:18PM  
Apr-29-19 10:20AM  
Apr-10-19 01:40PM  
Mar-19-19 08:30AM  
Feb-26-19 08:30AM  
Feb-25-19 08:30AM  
Feb-05-19 08:30AM  
Jan-23-19 08:00AM  
Jan-22-19 02:15PM  
Jan-07-19 08:30AM  
Jan-03-19 08:30AM  
Dec-11-18 08:30AM  
Dec-04-18 08:30AM  
Nov-21-18 02:53PM  
Nov-13-18 08:30AM  
Nov-12-18 08:30AM  
Oct-02-18 08:00AM  
Sep-27-18 08:30AM  
Sep-25-18 08:30AM  
Sep-24-18 08:00AM  
Sep-17-18 08:43AM  
Aug-29-18 08:30AM  
Aug-20-18 08:30AM  
Aug-13-18 09:25AM  
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; and Orano Med to develop CLR 12120 Series. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CARUSO JAMES VPresident and CEOMar 04Buy1.705,1008,65986,401Mar 05 05:45 PM
Longcor JarrodChief Business OfficerDec 28Buy1.3529,63040,000102,148Dec 28 04:31 PM
CARUSO JAMES VPresident and CEODec 28Buy1.3537,03750,00081,301Dec 28 04:31 PM
Elefant DovChief Financial OfficerDec 28Buy1.357,4079,99911,755Dec 28 04:30 PM
Elefant DovChief Financial OfficerJun 05Buy1.154,3484,9784,348Jun 08 04:08 PM
Longcor JarrodChief Business OfficerJun 05Buy1.1565,21874,67572,518Jun 08 04:08 PM
CARUSO JAMES VPresident and CEOJun 05Buy1.1521,74024,89244,264Jun 08 04:07 PM
HILL STEPHEN ADirectorJun 04Buy1.0818,00019,43818,000Jun 08 04:12 PM